Department of Medical Laboratory Science, The Third Xiangya Hospital, Central South University, Changsha, China.
The Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Cancer Research Institute, Central South University, Changsha, China.
J Clin Lab Anal. 2020 Aug;34(8):e23298. doi: 10.1002/jcla.23298. Epub 2020 Jul 22.
Cyclin D1 is an essential part of oncogenic transformation. We previously proved that cyclin D1 was upregulated in nasopharyngeal carcinoma (NPC) and promoted the NPC cell proliferation. But the association between cyclin D1 and the clinical outcome of NPC has not yet been determined. The study explores the possible relevance between the cyclin D1 expression and clinical parameters and its predictive value of prognosis in NPC patients.
We analyzed the clinical data from 379 NPC patients and 112 non-NPC patients in our previous study, which made further statistics. Receiver operating curve (ROC) was applied to select the optimal cutoff points. By analyzing the clinical data from 101 NPC patients using Chi-squared test, we estimated the relationship between the cyclin D1 expression level and clinicopathological parameters. We also used Kaplan-Meier method and log-rank test assess and compared the disease-free survival (DFS) rate and overall survival (OS) rate. The Cox proportional hazards model was adopted to perform the univariate and multivariate analyses.
Receiver operating curve analysis reported that cyclin D1 was used to differentiate between NPC patients and non-NPC patients (P < .001, sensitivity: 53.6%, specificity: 85.7%, AUC = 0.752). Cyclin D1 was positively correlated with lymph node metastasis (P = .015). A survival analysis of the 101 NPC patients indicated that the positive expression of cyclin D1 was predictive of a good prognosis (DFS: P = .010, OS: P = .019). Multivariate analysis showed that cyclin D1 could be used independently to predict NPC patients' prognosis (DFS: P = .038).
The overexpression of cyclin D1 is a good prognostic marker for NPC.
细胞周期蛋白 D1 是致癌转化的重要组成部分。我们之前证明细胞周期蛋白 D1 在鼻咽癌（NPC）中上调，并促进 NPC 细胞增殖。但是，细胞周期蛋白 D1 与 NPC 的临床结果之间的关联尚未确定。本研究探讨了细胞周期蛋白 D1 表达与临床参数之间的可能相关性及其对 NPC 患者预后的预测价值。
我们分析了我们之前研究中 379 例 NPC 患者和 112 例非 NPC 患者的临床数据，并进行了进一步的统计。应用接收者操作曲线（ROC）选择最佳截断点。通过对 101 例 NPC 患者的临床数据进行卡方检验，我们估计了细胞周期蛋白 D1 表达水平与临床病理参数之间的关系。我们还使用 Kaplan-Meier 方法和对数秩检验评估和比较无病生存率（DFS）和总生存率（OS）。采用 Cox 比例风险模型进行单因素和多因素分析。
ROC 分析报告称，细胞周期蛋白 D1 可用于区分 NPC 患者和非 NPC 患者（P<.001，敏感性：53.6%，特异性：85.7%，AUC=0.752）。细胞周期蛋白 D1 与淋巴结转移呈正相关（P=0.015）。对 101 例 NPC 患者的生存分析表明，细胞周期蛋白 D1 的阳性表达预示着较好的预后（DFS：P=0.010，OS：P=0.019）。多因素分析表明，细胞周期蛋白 D1 可独立用于预测 NPC 患者的预后（DFS：P=0.038）。
细胞周期蛋白 D1 的过表达是 NPC 的良好预后标志物。
